Cancer Watch

Great to see the @NHSEngland “liquid first” pilot program report on ctDNA NGS testing at ?lung cancer presentation now out: highlights performance outcomes of testing and economics nationally. rb.gy/iwbesh. Am discussing ctDNA in more detail at #ELCC26 Join me to!

This is a massively important trial —you rarely see this. Important for the field and for the region. It's time to reflect on PD1 dosing… ! Bravo @VanitaNoronha et al! @OncoAlert @JCO_ASCO @TataMemorial @ASCO

🌟Wow - Important de-escalation trial in ICI challenging the “more is always better” paradigm in oncology Optimizing dose, duration, frequency of ICIs maintain anti-tumor benefit with reducing toxicity, cost, and overtreatment = more patient-friendly ICI @pash22 @oncology_bg

Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. ja.ma/4qpGFIt

#FDA approves a treatment for unresectable or metastatic HER2-positive breast cancer. ow.ly/gApl50XJP1c

📣 FDA Approval of T-DXd in 1st Line HER2-Positive Breast Cancer! @DrChoueiri @BreastCancerNow @BreastDocUK @OncLive @oncodaily @BMJOncology @PBCC @BreastCancerCCS fda.gov/drugs/drug-app…

Starting now in📍Barcelona… @myESMO 2025 #AdvancedCourse in #BiliaryMalignancies that I co-chair with #JulienEdeline (always a pleasure ☺️) Dates for 2026 almost ready so if you are not here today, keep an eye on the next call and apply for next year🙃 esmo.org/about-esmo-mee…

📽️Watch video on The Human Crisis in Cancer here: youtube.com/watch?v=pHJKxi… 🎧 In our podcast, Dr Gary Rodin, @gary_rodin, joins us in discussing the Commission: thelancet.com/multimedia/pod…

Great to see the @NICEComms re-review/approval of #abiraterone in #ProstateCancer . Demonstrating new process for re-reviewing negative @NICEComms decisions when medicines become #generic or #biosimilar @pash22 @CMO_England @ProstateUK @ProfKarolSikora nice.org.uk/news/articles/…

@DrMarkLythgoe @NICEComms @pash22 @CMO_England @ProstateUK @ProfKarolSikora This is good news - do you think we could see bevacicumab in first line #colorectal cancer? @IanWalker_CRUK @ColonCancerUK @bowelcanceruk

🏃‍♂️💚 We’re so thankful to Anton Semelroth Jr., who ran the Marine Corps Marathon on October 26 in honor of his grandpa, Dick, raising $3,490 for the Cholangiocarcinoma Foundation, helping support patients and families affected by this disease. “I am grateful to have had the honor of running for both my grandpa and the Cholangiocarcinoma Foundation… Though my race has come to an end, Děda’s fight continues—and just as he was there for me on race day, I’ll be there for him every step of the way.” Thank you, Anton, for honoring your grandfather and helping raise awareness and hope for those affected by cholangiocarcinoma. give.cholangiocarcinoma.org/fundraiser/648….

Disappointing early look at tarlatamab in #EGFR NSCLC after #SCLC transformation @JCOPO_ASCO from @alissajcooper et al. Small numbers but out of 14, only 1 response (7%). May reflect heavy pretreatment and PS but optimism somewhat tempered here. ascopubs.org/doi/10.1200/PO…

Treatment after EVP in bladder cancer is undefined. Izalontamab brenitecan (HER2/3 TROP2 ADC) has good activity in bladder+lung cancer. A global randomised phase III has started enrolment 👉 Iza Bren alone vs platinum chemo in previously treated pts (including EVP). @OncoAlert

“I’d never heard of men getting breast cancer before." Head to our website to read John’s experience of breast cancer and how he found support with @TheMensVMU breastcancernow.org/about-us/news-…

Really good exchange with @GK_Olympus from @ELlokGr at #ESMO25. #Lungcancer remains one of the biggest challenges across Europe - collaboration on policy & access is key if we want to close the gaps between countries. #LCSM

Thankful to @myESMO for the opportunity to present our study with co-authors @kjmeetswrld @DrMarkLythgoe at #ESMO25 on the state of the global medical oncology workforce. We identified a total of 82,995 medical oncologists in practice across the globe. Disparities exist in accessing an oncologist particularly in lower middle- and low-income countries.

After #Tecentriq and #Opdivo, now #Keytruda @oncodaily @OncoAlert

Have you or a loved one experienced cancer? Your voice matters. Join our Patient Involvement Panel at our Centre for Drug Development and help shape the future of clinical trials. No research experience needed—just your lived experience and passion to make a difference. Join online meetings, share your views, and be paid for your time. Apply by 8 Sept here: bit.ly/4g1ZAEW #CancerResearch #PatientVoice #ClinicalTrials #CRUKInvolvement

@DrSanjayPopat @WHO Ha ha indeed - this is an interesting article summarising bpspubs.onlinelibrary.wiley.com/doi/10.1111/bp…

For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @WHO INN explainer tinyurl.com/49bxfn4t

Among cancer patients, receiving #COVID19 booster vaccines led to a 29-30% reduction in hospitalizations and ICU admissions. ja.ma/44OHvVG